CANCTema Oncology ETF
Seeks to provide long-term growth.
By Tema Global Limited · Launched 2023
0.75%
#3,765 of 5,562 · expensive
$176M
#2,398 of 5,562 · mid-size
+50.1%
2 years
#3,110 of 5,562 · seasoned
Performance
Total-return NAV · USDTotal-return NAV, USD. Net of fund fees, before tax.
Classification
How Beacon categorizes this fundWhat it actually holds
By weightConcentration
Top 10 holdings = 43.1% of fundmoderately concentrated
Asset allocation
By sector
Risk profile
Last 12 months · Sharpe & Sortino need 3+ yearsYear-on-year price swings
Worst peak-to-trough loss
Needs 3+ years of history
Needs 3+ years of history
Where to buy
Listing
- Exchange
- NASDAQ Global Select Market
Full fund details
- Objective
- Seeks to provide long-term growth.
- Strategy
- Invests primarily in publicly listed companies deriving at least 50% of revenues from oncology. The Adviser uses internal research and analysis to select companies, focusing on those attractively valued compared to fundamentals. The Fund generally holds 15 to 100 companies, with a market cap of at least $100 million and a three-month average daily traded value of at least $500,000. A significant portion of assets will be in the U.S. and Europe, and the Fund may invest in foreign securities and engage in securities lending.
- Inception date
- August 14, 2023
- Fund family
- Tema Global Limited
Similar ETFs
Closest matches by profileOur take
Structural notes on how this fund behaves. Read our guide on the 6 warning signs.
Thematic ETF — launched after the rally
Thematic funds are typically launched after a theme has delivered its strong returns. Morningstar's 2024 Global Thematic Funds Landscape finds that only about 1 in 10 thematic funds have survived and beaten a broad global equity benchmark over the past 15 years — roughly 60% have been closed outright. The narrative is always compelling; the track record rarely is.
Source: Morningstar, 'Global Thematic Funds Landscape' (2024)
Why we flagged this: Narrow thematic name, launched in the last 3 years, $176M in assets (under our $500M threshold).
Educational analysis of structural product characteristics. Not investment advice. Always read the fund prospectus and consult a qualified advisor before investing. More
What's next?
You've reviewed CANC. Save it to your watchlist to track it alongside the other funds you're weighing.
Data updated on 2026-06-19